articleThe LancetJul 1, 2010Closed access

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

MWM. William AudehJCJames CarmichaelRTRichard T. PensonMFMichael FriedländerBPBethan Powell

Cedars-Sinai Medical Center · AstraZeneca (United Kingdom) · +17 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

2,283
total citations
FWCI
98.22
Percentile
100%
References
58
Citations per year

Authors

15

Topics & keywords

Topics
Keywords
  • Olaparib
  • Medicine
  • PARP inhibitor
  • Cohort
  • Internal medicine
  • Ovarian cancer
  • Adverse effect
  • BRCA mutation
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding